Online exercise program for children and teens after medulloblastoma treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Children who survive medulloblastoma often face long-term cognitive and physical side effects from surgery, chemotherapy and radiotherapy. This pilot delivers individualized exercise sessions remotely via video conferencing, with supervised sessions three times weekly for 12 weeks. The program targets survivors within 36 months of completing therapy and excludes those with progressive disease or who cannot walk without support. The main goal is to determine whether this home-based approach is feasible and scalable across participating centers.

Why it matters

Who can join: the full rules

Inclusion Criteria: Completed therapy for medulloblastoma, including craniospinal radiation therapy, within 36 months before study entry.

\-

Exclusion Criteria: Inability to walk without support. Progressive disease.

\-

Where it's running

• Queen Silvia C hildren´s Hospital
  Gothenburg, Sweden Recruiting
• Technical University Munich
  München, Germany Not yet recruiting

Study contacts

• Study coordinator: Aron Onerup, MD, PhD
• Email: aron.onerup@gu.se
• Phone: +46766185619

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cognitive training with real-time brain feedback for childhood medulloblastoma survivors

  This study tests whether real-time brain feedback using rt-fMRI or rt-fNIRS can help children and young adults who survived childhood medulloblastoma improve attention and working memory.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07830134

• B7-H3 CAR T cells for recurrent brain tumors in kids and young adults

  This early-phase trial tests a personalized CAR T-cell therapy called B7-H3 CAR T for children and young adults with recurrent or progressive brain tumors.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07390539

• Liothyronine with BIT chemotherapy for relapsed medulloblastoma in kids and young adults

  This study tests Liothyronine (L-T3) with a BIT chemotherapy regimen in children and young adults whose medulloblastoma has come back or progressed after standard treatment.

  Recruiting at 2 sites Phase 1/2 University of California, San Francisco · San Francisco, California and 2 other locations · NCT07346157

• Identifying new treatment targets for childhood brain tumors

  This study is trying to find new ways to treat a rare brain tumor in kids by looking at genetic markers that could make them respond better to a type of cancer drug used for breast cancer.

  Recruiting Early Phase 1 Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma, ROMA · NCT06959979

• Intrathecal topotecan with maintenance chemotherapy after consolidation for high‑risk embryonal brain tumors in children under 6

  This study will test whether monthly intrathecal topotecan plus a year of oral maintenance chemotherapy after high‑dose consolidation is feasible and tolerable for children under 6 with high‑risk embryonal brain tumors.

  Recruiting at 12 sites Early Phase 1 C17 Council · Calgary, Alberta and 12 other locations · NCT06942039

• Immunotherapy using personalized T cells for pediatric brain tumors

  This study is testing a new treatment using personalized immune cells to help young children with certain brain tumors that haven't completely gone away after standard treatment.

  Recruiting Phase 1 Children's National Research Institute · Washington D.C., District of Columbia · NCT06193759

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.